76 related articles for article (PubMed ID: 3079379)
1. Antimetabolites.
Allegra CJ; Grem JL; Yeh GC; Chabner BA
Cancer Chemother Biol Response Modif; 1988; 10():1-22. PubMed ID: 3079379
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of resistance to antifolates, a review.
Banerjee D; Ercikan-Abali E; Waltham M; Schnieders B; Hochhauser D; Li WW; Fan J; Gorlick R; Goker E; Bertino JR
Acta Biochim Pol; 1995; 42(4):457-64. PubMed ID: 8852336
[TBL] [Abstract][Full Text] [Related]
3. [Clinical pharmacology of anticancer agents [Part 5] Antimetabolites (2)].
Nakamura T; Ueda T; Uchida M
Gan To Kagaku Ryoho; 1992 Mar; 19(3):409-20. PubMed ID: 1543370
[TBL] [Abstract][Full Text] [Related]
4. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
Zhao R; Babani S; Gao F; Liu L; Goldman ID
Clin Cancer Res; 2000 Sep; 6(9):3687-95. PubMed ID: 10999762
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
Zhao R; Gao F; Babani S; Goldman ID
Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
9. Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application.
McIvor RS
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S50-4. PubMed ID: 8971409
[TBL] [Abstract][Full Text] [Related]
10. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
[TBL] [Abstract][Full Text] [Related]
11. [Mice transduced with double-mutant dihydrofolate reductase-cytidine deaminase fusion gene attained protection from high dose chemotherapy].
Lu P; Lu Y; Pang K; Wang SB; Chen JQ; Xu HM; Wang JK; Zhao SC
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):998-1001. PubMed ID: 16194358
[TBL] [Abstract][Full Text] [Related]
12. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
McGuire JJ; Magee KJ; Russell CA; Canestrari JM
Oncol Res; 1997; 9(3):139-47. PubMed ID: 9220499
[TBL] [Abstract][Full Text] [Related]
13. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs.
Cole PD; Smith AK; Kamen BA
Cancer Chemother Pharmacol; 2002 Aug; 50(2):111-6. PubMed ID: 12172974
[TBL] [Abstract][Full Text] [Related]
14. Resistance mechanisms to methotrexate in tumors.
Bertino JR; Göker E; Gorlick R; Li WW; Banerjee D
Stem Cells; 1996 Jan; 14(1):5-9. PubMed ID: 8820944
[TBL] [Abstract][Full Text] [Related]
15. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
[TBL] [Abstract][Full Text] [Related]
17. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
[TBL] [Abstract][Full Text] [Related]
18. [Biochemical modulation in cancer chemotherapy].
Kawasaki H; Nobori T; Kamiya H; Sakurai M
Gan To Kagaku Ryoho; 1985 Apr; 12(4):815-29. PubMed ID: 3985645
[TBL] [Abstract][Full Text] [Related]
19. Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay.
Lingg RM; Hempel G; Rots MG; Van Zantwijk CH; Boos J; Kaspers GJ
Cancer Chemother Pharmacol; 2005 Sep; 56(3):322-7. PubMed ID: 15868145
[TBL] [Abstract][Full Text] [Related]
20. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.
Chen ZS; Lee K; Walther S; Raftogianis RB; Kuwano M; Zeng H; Kruh GD
Cancer Res; 2002 Jun; 62(11):3144-50. PubMed ID: 12036927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
